President Donald Trump told reporters outside the White House on Friday that he knew "nothing about" reports he had signed off on a plan to remove FDA Commissioner Marty Makary, even as a coalition of pro-life groups, pharmaceutical industry leaders, and Make America Healthy Again advocates fought publicly over the embattled health official's future.
"I've been reading about it, but I know nothing about it," Trump said when asked about the Wall Street Journal's reporting that he had approved Makary's ouster. Asked directly whether he planned to bring in a new FDA head, the president answered with a flat "no, no."
The denial came the same day the Journal reported that Trump had signed off on a plan to fire Makary, a former oncology surgeon confirmed to lead the FDA in March 2025. But the friction had been building for days. Earlier in the week, the Journal reported that Trump had pressured Makary to fast-track approval for flavored nicotine vapes, and that Makary pushed back.
When reporters pressed Trump on what he'd discussed with Makary, the president offered a two-word summary: "nothing much."
What makes Makary's position so precarious is the sheer range of constituencies unhappy with him, and the fact that they want opposite things.
Pro-life groups have accused Makary of slow-walking a safety review for the abortion pill mifepristone. SBA Pro-Life America president Marjorie Dannenfelser issued a statement calling for his removal, framing the stakes in blunt political terms:
"This is a five-alarm crisis for the pro-life movement and for the GOP. The GOP cannot win without its base and simply will not get the enthusiasm that drives turnout without leadership from the top."
That complaint resonates with a broader frustration among social conservatives who expected the Trump administration to move decisively on abortion-related policy at the FDA. The ongoing friction over the Biden-era abortion pill memo within the administration only sharpens the point.
From the other direction, pharmaceutical and biotech firms have pushed back against Makary's management. John Crowley, head of the Biotechnology Innovation Organization, condemned what he called indiscriminate personnel cuts at the FDA in a recent op-ed:
"Some of the administration's recent efforts to reform the federal government through aggressive and often indiscriminate personnel cuts have lacked the strategic insights necessary to modernize and reform our nation's health care agencies, especially the FDA."
The Washington Examiner reported that under Makary, drug rejections increased, missed application review deadlines tripled in 2025, and approvals dropped, developments that alarmed an industry already worried about U.S. biotech competitiveness. Biotech leaders warned about canceled advisory meetings and poor communication with drug developers.
So Makary drew fire from social conservatives for moving too slowly on mifepristone, from industry for moving too slowly on drug approvals, and from the White House for not moving fast enough on flavored vapes. That is a difficult position for any agency head, and an impossible one when the president's patience runs short.
Not everyone wanted Makary gone. Figures aligned with Robert F. Kennedy Jr.'s Make America Healthy Again movement mounted a vocal defense, arguing that the real opposition came from entrenched industry interests.
Kelly Ryerson, an author and popular advocate known as Glyphosate Girl, told Fox News Digital that Makary was an asset, not a liability. "Dr. Makary is an ally in the MAHA movement," she said. "It is not surprising that his uncaptured approach to protecting human health has been met with the swamp calling for his firing."
Ryerson pointed specifically to the vape controversy. "The criticism is that he didn't approve flavored vapes quickly enough. The mothers who don't want their kids smoking find that reasoning alarming."
This is a real tension within the president's coalition. Trump's administration has pursued an aggressive reform agenda at the FDA, including executive orders directing the agency to fast-track certain drug reviews. But the MAHA wing sees an FDA commissioner willing to resist industry pressure as exactly the kind of reformer the movement needs.
Turning Point USA-affiliated podcaster Alex Clark put it more forcefully in a Friday post on X, writing that "the attacks against FDA Commissioner Marty Makary are coming from Big Pharma and the media outlets financially dependent on pharmaceutical advertising for survival." Clark urged the president not to fire Makary, calling him "one of the strongest representatives of the MAHA movement inside the federal government."
Popular food blogger Vani Hari, a prominent figure in the MAHA movement, wrote that a Makary ouster "would be a horrible move."
Trump's Friday comments appeared to tamp down the story. But the situation moved quickly after that.
Newsmax reported, citing the Wall Street Journal, that Trump had approved a plan to remove Makary, though people familiar with the matter cautioned the decision was not yet final. The report noted months of internal conflict over flavored vaping approvals, abortion-pill policy, vaccine decisions, and broader complaints about Makary's management.
Then came the end. The Associated Press reported that Makary resigned after a turbulent 13-month tenure. An administration official told the AP that the decision to remove Makary was made by Health Secretary Robert F. Kennedy Jr. and approved by the White House, a sequence that puts Kennedy, not Trump, in the role of the official who pulled the trigger.
Trump confirmed the resignation publicly. "He's a great doctor, and he was having some difficulty," the president told reporters. Makary's resignation note was brief: "Please accept my resignation, effective today."
The New York Post reported that the immediate trigger appeared to be Makary's handling of vape policy, including blocking implementation of an approval before Trump intervened. But the accumulated weight of complaints from pro-life activists, pharmaceutical executives, and administration officials over staffing, rare-disease treatment approvals, and abortion drug policy all contributed.
Trump said Kyle Diamantas, the FDA's chief for foods, is expected to serve as acting commissioner.
Makary's departure fits a broader pattern in this administration. Trump has shown little hesitation in removing officials who fall out of step with his agenda, whether the disagreement involves policy substance or execution speed.
The president removed Homeland Security Secretary Kristi Noem earlier this year after a high-profile hearing debacle. The administration has also moved to terminate National Science Board members in what has become a sustained effort to reshape federal personnel across agencies.
White House spokesman Kush Desai offered the standard framing: "President Trump has assembled the most experienced and talented administration in history, an administration that continues to focus on delivering more historic victories for the American people."
That is the official line. The reality is messier. Makary was not a holdover bureaucrat or a Democratic appointee. He was Trump's own pick, confirmed just over a year ago, and he still couldn't satisfy the competing demands of the president's coalition.
Several things remain unclear. Fox News Digital contacted the White House, HHS, the FDA, BIO, and SBA Pro-Life America for additional comment. The responses, if any, were not included in reporting.
The deeper question is whether any FDA commissioner can thread the needle this administration requires. Pro-life groups want aggressive action on mifepristone. The biotech industry wants faster approvals and fewer personnel disruptions. The MAHA movement wants an agency head willing to challenge pharmaceutical influence. And the White House wants someone who does what the president asks, when the president asks it.
Makary, by most accounts, tried to serve multiple masters and satisfied none of them. His successor will face the same impossible math, with the added knowledge that the last person in the chair lasted barely a year.
Washington has a way of chewing through reformers who try to please everyone. The next FDA commissioner would do well to pick a lane, and make sure it's the president's.